James P. Allison

James Patrick Allison (born August 7, 1948) is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.

His discoveries have led to new cancer treatments for the deadliest cancers.

He is also the director of the Cancer Research Institute (CRI) scientific advisory council.

He has a longstanding interest in mechanisms of T-cell development and activation, the development of novel strategies for tumor immunotherapy, and is recognized as one of the first people to isolate the T-cell antigen receptor complex protein.

Allison was born on August 7, 1948, in Alice, Texas, the youngest of three sons of Constance Kalula (Lynn) and Albert Murphy Allison.

He was inspired by his eighth-grade math teacher to pursue a career in science, spending a summer in a National Science Foundation–funded summer science-training program at the University of Texas, Austin, and completing high-school biology by correspondence course at Alice High School.

Allison earned a Bachelor of Science degree in microbiology from University of Texas, Austin, in 1969, where he was a member of Delta Kappa Epsilon fraternity.

He earned his doctor of philosophy degree in biological science in 1973, also from UT Austin, as a student of G. Barrie Kitto.

From 1974 to 1977, Allison worked as postdoctoral fellow at Scripps Clinic and Research Foundation in California.

In 1977, Allison and a colleague, G. N. Callahan, reported in a letter to Nature that they had found evidence that the immune system was prevented from attacking cancer cells due to antigens’ association with additional proteins.

Finding the factors that inhibited the immune attack on cancer has been key to developing checkpoint-blockade cancer immunotherapies.

In 1982, Allison first discovered the T-cell receptor.

Then he worked as assistant biochemist and assistant professor at MD Anderson to 1984.

He was appointed a professor of immunology and director of the Cancer Research Laboratory at the University of California, Berkeley in 1985 and was concurrently appointed professor at the University of California, San Francisco from 1997.

Allison's research to elucidate mechanisms of T-cell responses was conducted in the 1990s at the University of California, Berkeley.

In the early 1990s, Jim Allison showed that CTLA-4 acts as an inhibitory molecule to restrict T-cell responses.

In 1996, Allison was the first to show that antibody blockade of a T-cell inhibitory molecule (known as CTLA-4) could lead to enhanced anti-tumor immune responses and tumor rejection.

This concept of blocking T-cell inhibitory pathways as a way of unleashing anti-tumor immune responses and eliciting clinical benefit laid the foundation for the development of other drugs that target T-cell inhibitory pathways, which have been labeled as "immune checkpoint therapies".

In 2004, he moved to the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City to become the director of the Ludwig Center for Cancer Immunotherapy and the chair of the immunology program as well as the Koch chair in immunologic studies and attending immunologist at the Memorial Sloan-Kettering Cancer Center.

He was a professor of Weill Cornell Medicine and co-chair of the Department of Graduate Program in Immunology and Microbial Pathogenesis at Weill Cornell Graduate School of Medical Sciences from 2004 to 2012, and also a Howard Hughes Medical Institute (HHMI) investigator until 2012, when he left to join the M. D. Anderson Cancer Center in 2012.

According to a quantitative analysis, Allison was the top-ranking recipient of the most prestigious international science awards in the period 2010–2019, having received 13 of the top 40 such awards in any field of science.

This work ultimately led to the clinical development of ipilimumab (Yervoy), which was approved in 2011 by the FDA for the treatment of metastatic melanoma.

Allison's research is in molecular immunology of the T-cell antigen receptor complex, co-stimulatory receptors, and other molecules involved in T-cell activation.

He is particularly interested in finding signals that lead to differentiation of naive T-cells and also those that determine whether antigen receptor engagement will lead to functional activation or inactivation of T-cells.

Once defined, the basic studies are used to develop new strategies for the treatment of autoimmune diseases and immunotherapy of cancer.

Most recently he has been interested in understanding the immune responses in cancer patients who respond to immunotherapy.

He established the immunotherapy platform at MD Anderson Cancer Center to study immune responses in cancer patients.

In 2011 Allison won the Jacob Heskel Gabbay Award for Biotechnology and Medicine and was awarded the American Association of Immunologists Lifetime Achievement Award.

Since 2012 he has been chair of immunology at M.D. Anderson.

He is a member of the National Academy of Sciences and the National Academy of Medicine (formerly Institute of Medicine), and is a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science.

He is director of the Cancer Research Institute scientific advisory council.

Previously, he served as president of the American Association of Immunologists.

He is on the Research Advisory Board of Candel Therapeutics and Lytix Biopharma.

Allison serves as a commentator in the Cancer documentary.

Allison trained at Scripps Research under tumor-immunologist Ralph Reisfeld, Ph.D., professor emeritus, researching human leukocyte antigens (HLA) and T-cells and exploring the role HLA proteins play in enabling the immune system to distinguish self from invaders.

In 2013 he shared the Novartis Prize for Clinical Immunology.

In 2014, he was awarded the Breakthrough Prize in Life Sciences; in 2018, he shared the Nobel Prize in Physiology or Medicine with Tasuku Honjo.

In 2014 he shared the first Tang Prize in Biopharmaceutical Science with Tasuku Honjo, won the 9th Annual Szent-Györgyi Prize for Progress in Cancer Research of the National Foundation for Cancer Research, received the $3 million Breakthrough Prize in Life Sciences, the Canada Gairdner International Award, the Louisa Gross Horwitz Prize, the Massry Prize and the Harvey Prize of the Technion Institute of Technology in Haifa.

In 2015, he received the Lasker-DeBakey Clinical Medical Research Award.

and Paul Ehrlich and Ludwig Darmstaedter Prize.